Left ventricular hypertrophy (LVH) is a powerful independent risk predictor for cardiovascular disease and reversal of LVH has become a primary goal of antihypertensive management. Recent evidence has confirmed that most hypertensive patients will benefit from a low-dose combination strategy to manage their hypertension, and two trials have recently examined the effect of this strategy on left ventricular mass. The REASON study (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd study) compared the low-dose combination of an angiotensin-converting enzyme (ACE) inhibitor and a diuretic with b-blocker monotherapy in hypertensive patients with LVH, and the PICXEL study (Preterax In a double-blind Controlled study versus Enalapril in LVH) compared the same lowdose combination with ACE inhibitor monotherapy in hypertensive patients with echocardiographic LVH. The REASON study demonstrated that the low-dose combination produced a significantly greater change in left ventricular mass after 1 year than the b-blocker, despite inducing a similar change in mean blood pressure. Additionally, perindopril/indapamide reduced central (carotid) and peripheral (brachial) systolic blood pressure (SBP) and pulse pressure (PP) to a significantly greater extent than b-blocker, and these benefits were more pronounced for the central values; LVH is affected more by central rather than peripheral haemodynamic changes. Results of the analysis of the PICXEL study showed a significantly greater decrease in LVH parameters and blood pressure over 1 year in favour of the low-dose combination. This reduction cannot be entirely explained by the better efficacy of the low-dose combination on blood pressure reduction.
Introduction
It is now well recognised that it is essential to manage and prevent cardiovascular target-organ damage in the treatment of hypertension in order to avoid the emergence of cardiovascular complications. [1] [2] [3] Left ventricular hypertrophy (LVH) is a powerful independent risk predictor for cardiovascular disease. Hence, LVH has strong links with cardiovascular morbidity and mortality in patients with essential hypertension. [1] [2] [3] More importantly, regression of LVH has been demonstrated to substantially reduce the risk for cardiovascular events. [4] [5] [6] [7] Thus, targeting LVH has become an important goal of antihypertensive management, and all current guidelines are congruent in that the presence of LVH should lead to more aggressive treatment.
Clinical trials conducted in the past few years indicate that various antihypertensive agents produce regression of LVH, and thereby improve the prognosis. 7, 8 A meta-analysis showed that, for the same reduction in blood pressure (BP), left ventricular mass (LVM) regression is more pronounced with blocking of the renin-angiotensin system than with other antihypertensive therapeutic principles. 9, 10 Furthermore, much evidence has been accumulated to warrant greater attention being paid to the importance of increased systolic blood pressure (SBP) as a major risk factor for increased LVM, increased pulse pressure (PP), and arterial stiffness. 4 Unfortunately, normalisation of BP rarely occurs when the treatment involves administration of monotherapy. Recent evidence has shown that most patients will benefit from combination of drugs from different antihypertensive classes, rather than titration of monotherapy. 1 Moreover, there are physiological reasons for the better performance of a combination strategy. 11 Indeed, the first-line, lowdose combination of the ACE inhibitor perindopril (2 mg) and indapamide (0.625 mg) was shown to have a favourable efficacy/safety ratio 12 and better antihypertensive efficacy than monotherapy with enalapril, 13 losartan, 14 and irbesartan. 15 This therapeutic strategy of a fixed-dose combination was assessed in hypertensive patients in the REASON study (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd study) compared with b-blocker monotherapy [16] [17] [18] [19] [20] and, more recently, in the PICXEL study (Preterax In a doubleblind Controlled study versus Enalapril in LVH) in hypertensive patients with LVH compared with ACE-inhibitor monotherapy. 21 After the echocardiographic substudy of LIFE (Losartan Intervention For End point reduction in hypertension), 7 PICXEL is the largest study on regression of LVH, and the first to compare a combination regimen with monotherapy using an antihypertensive class generally considered to be one of the most effective in the regression of LVH. 21 The REASON trial: LVH benefits of low-dose ACE inhibitor/diuretic combination vs b-blocker
The REASON trial is an international, multicentre, randomised, double-blind investigation with two parallel groups. [16] [17] [18] [19] [20] This trial compared the antihypertensive effects of the low-dose combination of perindopril (2 mg) and indapamide (0.625 mg) with the b-blocker atenolol (50 mg). It was conducted in patients aged 18-84 years with sustained mildto-moderate essential hypertension, defined as SBP X160 mmHg and o210 mmHg, and/or diastolic blood pressure (DBP) X95 mmHg and o110 mmHg.
The main goal of the REASON trial was to determine whether the low-dose perindopril/indapamide combination decreased SBP and PP more than atenolol and, if so, whether this decrease was predominantly caused by reducing aortic pulse wave velocity (PWV) (measured automatically) and wave reflections (determined on the basis of pulse wave analysis and applanation tonometry).
Following the wash-out placebo period, 469 patients were randomised to receive a 1-year period of treatment with either the low-dose combination of perindopril (2 mg) and indapamide (0.625 mg) (n ¼ 235) or atenolol (50 mg) (n ¼ 234). The dosage could be doubled after 3 months if SBP and/or DBP continued to exceed 160 mmHg and 90 mmHg, respectively. In all, 78% of patients completed the 12-month period of treatment. Cardiac output and total peripheral resistance were also measured at M0 and M12 using standard echocardiographic techniques.
The key results of the REASON trial have already been published, as have the results of several ancillary studies. [16] [17] [18] [19] [20] Figure 1 displays the various populations of patients analysed.
In the whole population, after 12 months of treatment, the low-dose combination of perindopril (2 mg) and indapamide (0.625 mg) induced significantly greater decreases in brachial SBP (À6.271.5 mmHg) and brachial PP (À5.571.0 mmHg) than the b-blocker atenolol alone (Po0.001) ( Table 1) . 17 This finding, which is more significant in the central than in the brachial artery, was confirmed in both the intention-to-treat (ITT) and per-protocol statistical analyses.
The REASON substudies: selective reduction in LVM and central BP
A substudy of the REASON trial 18 was conducted to determine whether LVM changes were significantly related to treatment with the low-dose combination of perindopril/indapamide or atenolol, and whether the changes in LVM were linked to brachial or central BP measurements, or both.
To address these questions, only data from patients not withdrawn from the global therapeutic protocol (n ¼ 469) and having complete haemodynamic measures at both baseline and 12 months (n ¼ 146) were used.
The results of this study have shown that the lowdose combination of perindopril/indapamide produces a significantly greater change in LVM than the standard comparator atenolol, despite inducing a similar change in mean BP (Tables 2 and 3) . 18 After 12 months, LVM and left ventricular mass index (LVMI) were significantly lower in the patients receiving perindopril/indapamide than in the patients receiving atenolol (P ¼ 0.0125 and 0.0121, respectively). The consistent differential effect on LVH is associated with an improvement in large artery function involving central wave reflections, which consequently brings about a selective change in central SBP and PP. In summary, the REASON study demonstrated that LVM lowering was more significant with the low-dose combination Echocardiography n=110
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protocol Figure 1 The study population in REASON. Per/Ind, low-dose combination of perindopril (2 mg) and indapamide (0.625 mg); Ate, atenolol (50 mg).
of perindopril/indapamide than monotherapy with atenolol, and that the intergroup difference in LVM was statistically linked to central, not brachial PP.
The mechanisms of SBP reduction with atenolol differ substantially from those of the perindopril/ indapamide combination. Atenolol reduction is essentially based on mean BP reduction, while perindopril/indapamide induces changes in arterial stiffness of conduit arteries and wave reflections. 19 The PICXEL study: benefits of low-dose combination in terms of LVH regression
The PICXEL study was a multicentre, randomised, double-blind, controlled study in hypertensive patients with echocardiographically determined LVMI4100 g/m 2 in women and LVMI4120 g/m 2 in men in nine different countries. 22 Its main objective was to specifically compare LVH reduction in hypertensive patients treated with either a fixed combination strategy or monotherapy with an established antihypertensive agent. Following a 4-week placebo period, patients received either the combination of perindopril (2 mg) and indapamide (0.625 mg) or enalapril (10 mg) for 52 weeks, with the possibility of doubling the dose twice (to perindopril 8 mg and indapamide 2.5 mg or enalapril 40 mg) to achieve BP control of 140/90 mmHg. A Central Echocardiography Committee, blinded to visit sequence, patient, and treatment, assessed the LVM in a final reading. The choice of an ACE inhibitor as a comparator was supported by the results of the meta-analysis of double-blind trials measuring the effects of antihypertensive therapy on LVM. 10 This analysis demonstrated a significant difference among the main medication classes (P ¼ 0.004). A À10% mass decrease in LVMI was recorded with ACE inhibitor.
In all, 556 hypertensive patients (47% men), with a mean age of 55 years, with SBP 164.4714.5 mmHg and DBP 98.678.5 mmHg as well as confirmed LVH at the central reading (LVMI ¼ 143.5728.7 g/m 2 ) were evaluated. Both treatment groups were comparable at baseline.
According to the intention-to-treat analysis, a significantly higher decrease in LVH parameters and BP over 1 year in favour of the low-dose combination of perindopril and indapamide compared with enalapril was demonstrated as shown in Table 4 . This reduction cannot be entirely explained by the better efficacy of the low-dose combination on BP reduction alone. After adjustment for the greater BP reduction, age, gender and baseline value, the LVMI reduction with perindopril/indapamide remained significantly superior. The full results of the PICXEL study will be available in 2005.
Discussion
The REASON study compared the antihypertensive effect of two antihypertensive first-line treatment strategies, the fixed combination of perindopril and indapamide vs monotherapy with atenolol. After 1 year's treatment, the two regimens resulted in similar reductions in mean BP and SBP. However, perindopril/indapamide reduced central (carotid) and peripheral (brachial) SBP and PP to a significantly greater extent than atenolol, and these benefits were expressed for central SBP and PP. It is well-known that LVM is affected more by central rather than peripheral haemodynamic changes, and the more pronounced effects of perindopril/indapamide on central SBP and PP lowering could explain the greater effect of the combination on LVM reduction. The results of this study are particularly important as the study design complies with criteria for informative trials on LVM reduction, that is, REA-SON has a sufficient number of patients, a representative population, a long duration (12 months), double-blind randomisation, and blinded central echocardiographic readings. 19 The PICXEL study further substantiates the results of REASON by demonstrating that, over 1 year of treatment, the clinical benefits of the fixed combination of perindopril/indapamide occur via significant reductions in BP and LVH, compared with enalapril alone. 21 There are physiological reasons for the better performance of a combination strategy. The ideal combination therapy should address counter-regulatory mechanisms, which can limit the efficacy of antihypertensive therapy. Thus, the key combination for better control of LVH should use agents with complementary modes of action to reduce the volume and resistance components of BP and left ventricular overload, or -ideally -drugs with similarly efficacies on the two haemodynamic components. The combination of a diuretic and an ACE inhibitor appears to be particularly appropriate for the following reasons:
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It combines control of both the volume and resistance components of BP. It minimises the activation of the renin-angiotensin system. It includes the non-BP-related effect of angiotensin II as a growth factor on the left ventricle and arterial wall.
In conclusion, the fixed low-dose of perindopril (2 mg)/indapamide (0.625 mg) is a potential first-line therapeutic approach in essential hypertension that causes a better improvement in central BP (aortic, carotid) than in brachial BP. This combination achieves significantly greater changes in LVM than the standard comparators atenolol or enalapril and confirms the effectiveness of a fixed combination approach compared with the monotherapy approach in hypertensive patients with or without LVM.
